CD274 and non-small cell lung carcinoma: In 2020, Valentinuzzi et al. [25] created a [18F]FDG PET radiomics signature (iRADIOMICS) consisting of the most promising radiomics features extracted by the [18F]-FDG images and able to predict the response of metastatic NSCLC (stage IV) to pembrolizumab compared to the clinical standards (PD-L1 immunohistochemistry and iRECIST).